Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADopt-VA: Lebrikizumab Vaccine Response in AD
NCT04626297Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap Vaccine Administration at 16 weeks and Percentage of Participants Who Have Positive Antibody Response to Meningococcus C Antigen 4 Weeks After Meningococcal Conjugate Vaccine (MCV) Administration at 16 weeks. Started Nov 2020; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04626297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626297.